So far, 2012 has been a terrific year for our biotechnology portfolio. It’s been great for biotech investors in general, despite the weak global economy. The Nasdaq Biotechnology Index (NBI), for example, is up 35%. The biotech picks in my investment letter, Technology Profits Confidential, have outperformed even these stellar returns.
To read the full, original article click on this link: Biotech Bonanza of 2012 - Business Insider
